Aromatase (CYP19) Polymorphism Between AI-responsive and AI-resistant Breast Cancer in Korea (CYP19)
Sponsor: Samsung Medical Center
Suspended
Because of economic issue, we could just enrolled total 150 patients.
A observational or N/A phase clinical study on Aromatase Inhibitor and CYP19, this trial is suspended. The trial is conducted by Samsung Medical Center and has accumulated 7 data snapshots since 2010. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
7 versions recorded-
Sep 2025 — Present [monthly]
Suspended
-
Sep 2024 — Sep 2025 [monthly]
Suspended
-
Jul 2024 — Sep 2024 [monthly]
Suspended
-
Jan 2021 — Jul 2024 [monthly]
Suspended
-
Jun 2018 — Jan 2021 [monthly]
Suspended
▶ Show 2 earlier versions
-
Apr 2018 — Jun 2018 [monthly]
Suspended
Phase: NA → None
-
Jan 2017 — Apr 2018 [monthly]
Suspended NA
First recorded
Jun 2010
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Samsung Medical Center
For direct contact, visit the study record on ClinicalTrials.gov .